COSCIENS Biopharma Inc. Common Stock
CSCI
CSCI was delisted on the 3rd of September, 2025.
12 hedge funds and large institutions have $65.8K invested in COSCIENS Biopharma Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0.04% less ownership
Funds ownership: 0.22% → 0.18% (-0.04%)
14% less funds holding
Funds holding: 14 → 12 (-2)
38% less capital invested
Capital invested by funds: $106K → $65.8K (-$39.8K)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
92% less call options, than puts
Call options by funds: $35K | Put options by funds: $412K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$18.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$59 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$29.8K |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$5.92K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4.92K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$222 |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$192 |
CSCI Hedge Fund Activity: Q4 2023 in Review
12 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in COSCIENS Biopharma Inc. Common Stock (CSCI) for Q4 2023, worth a combined $65.8K — down 38% from $106K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CSCI and 1 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 1 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $18.5K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $29.8K sold.
- 12 institutional investors held COSCIENS Biopharma Inc. Common Stock (CSCI) as of Q4 2023, down from 14 in Q3 2023.
- Funds reported $65.8K of COSCIENS Biopharma Inc. Common Stock stock for Q4 2023, down 38% quarter-over-quarter.
- 1 fund opened new COSCIENS Biopharma Inc. Common Stock positions in Q4 2023 and 3 closed out, a net change of -2 holders.
- The largest COSCIENS Biopharma Inc. Common Stock buyer in Q4 2023 was Citadel Advisors, an estimated $18.5K added.
- The largest COSCIENS Biopharma Inc. Common Stock seller in Q4 2023 was Two Sigma Securities, an estimated $29.8K sold.
Based on aggregated 13F filings for Q4 2023.